Legislative Proposal, Bill or Resolution, Regulation
CANADIAN ENVIRONMENTAL PROTECTION ACT AND REGULATIONS in respect of modern, science-based regulations to reflect rapidly changing new technologies
FOOD AND DRUGS ACT AND REGULATIONS in respect of minimizing regulatory burden and ensuring appropriate climate for the introduction of new technologies
Policies or Program
ACCESS & BENEFIT SHARING: TRIPS AGREEMENT in respect of protecting intellectual property and preventing increased uncertainty
ADVENTITIOUS PRESCENCE POLICY in respect of new agricultural biotechnology products
BIOSAFETY PROTOCOL in respect of Canada's participation in global discussions to ensure an enabling environment for safe new technologies
Clarify the administration of SR&ED program to ensure clinical trials and international research conducted in Canada qualifies as eligible expenses
Creation of a modern policy environment that recognizes international standards and reviews, and establishes clarity on data ownership for intellectual property
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies and Health (CADTH) and its Common Drug Review process (Health Canada)
FOOD LABELLING in respect of mitigating the unnecessary introduction of new labelling requirements for products already approved under current regulated process and in respect of maintaining harmonization of requirements with trading nations
IMPROVED TAXATION & INVESTMENT FRAMEWORK in respect of extending Canada's flow-through shares program to biotechnology companies for increased domestic investments.
IMPROVEMENTS TO THE Scientifc Research & Experimental Development TAX CREDITS in respect of updating the 20 yr old system by removing the punitive Canadian Controlled Private Companies restriction and increasing the expenditure limit for refundable credits
NOVEL FOODS in respect of maintaining a science-based regulatory system for novel foods derived from plant and animal biotechnology
PATENTED MEDECINES PRICES REVIEW BOARD (PMPRB) PRICE REVIEW to ensure new guidelines and directives do not create disincentives for the introduction of new treatments in Canada
RESEARCH & DEVELOPMENT (R&D) in respect on providing input to the government's expert panel on business R&D to improve incentives for research in Canada
SCIENCE & TECHNOLOGY STRATEGY in respect of encouraging a strong government focus to stimulate the development, use and retention of biotechnology products, processes and companies
SUBMISSION REVIEW PROCESS FOR BIOLOGICS, COST RECOVERY REVIEW to ensure Canada remains competitive overall and any new costs do not put bioloigics are a comparative disadvantage
Vaccine Funding - National Immunization Strategy - to re-establish federal leadership in providing provinces with funding for new vaccines under a renewed national immunization strategy framework
Vaccine contracting and supply
WORLD TRADE ORGANIZATION (WTO) in respect of Canada's contribution and participation to encourage a sound business climate and to faciliate Canada's access to European markets for genetically engineered agricultural and animal products
Policies or Program, Regulation
INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)
ORPHAN PRODUCTS to establish formal regulations, policies or programs to encourage the research, development and introduction of new technologies to treat "orphan" or neglected diseases
REGULATORY APPROVAL PROCESS FOR PLANTS WITH NOVEL TRAITS as NOVEL FOODS or INDUSTRIAL BIO_PRODUCTS in respect of an efficient science-based approach and allows for greater cooperation among and between government departments
Regulatory framework for subsequent entry biologics to ensure an appropriate and transparent appraoch for the safe introduction of biosimilars
Regulation
SUBSEQUENT ENTRY BIOLOGICS to establish formal regulations to prescribe the requirements for introduction of biosimilars and ensure the protection of intellectual property for first entry biologics
